Onychomycosis (Tinea Unguium) R&D Pipeline Analysis Report, Q4 2020
Onychomycosis (Tinea Unguium) Pipeline Overview
The Q4 Onychomycosis (Tinea Unguium) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Onychomycosis (Tinea Unguium), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Onychomycosis (Tinea Unguium) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Onychomycosis (Tinea Unguium) disease overview, Onychomycosis (Tinea Unguium) types, Onychomycosis (Tinea Unguium) symptoms, causes, and FDA/EMA approved treatment options.
Onychomycosis (Tinea Unguium) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Onychomycosis (Tinea Unguium) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Onychomycosis (Tinea Unguium) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 15 companies. Business profiles and contact details of the companies actively perusing Onychomycosis (Tinea Unguium) pipeline are assessed.
Onychomycosis (Tinea Unguium) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Onychomycosis (Tinea Unguium) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Onychomycosis (Tinea Unguium) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Onychomycosis (Tinea Unguium) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Onychomycosis (Tinea Unguium) Pipeline Market News and Developments during 2020
The Onychomycosis (Tinea Unguium) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Onychomycosis (Tinea Unguium) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Onychomycosis (Tinea Unguium) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Onychomycosis (Tinea Unguium), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Onychomycosis (Tinea Unguium) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Onychomycosis (Tinea Unguium) disease overview, Onychomycosis (Tinea Unguium) types, Onychomycosis (Tinea Unguium) symptoms, causes, and FDA/EMA approved treatment options.
Onychomycosis (Tinea Unguium) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Onychomycosis (Tinea Unguium) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Onychomycosis (Tinea Unguium) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 15 companies. Business profiles and contact details of the companies actively perusing Onychomycosis (Tinea Unguium) pipeline are assessed.
Onychomycosis (Tinea Unguium) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Onychomycosis (Tinea Unguium) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Onychomycosis (Tinea Unguium) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Onychomycosis (Tinea Unguium) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Onychomycosis (Tinea Unguium) Pipeline Market News and Developments during 2020
The Onychomycosis (Tinea Unguium) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Onychomycosis (Tinea Unguium) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Onychomycosis (Tinea Unguium) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 15 companies are included including Acea Biotech Inc, Almirall SA, Blueberry Therapeutics Ltd, CSA Biotechnologies LLC, DermBiont Inc, Exodos Life Sciences Limited Partnership, Hallux Inc, Hexima Ltd, Kaken Pharmaceutical Co Ltd, Moberg Pharma AB, Mycovia Pharmaceuticals, NAL Pharmaceuticals Ltd, Novabiotics Ltd, Photonamic GmbH & Co KG, Sanotize Research And Development Corp,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Onychomycosis (Tinea Unguium) pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Onychomycosis (Tinea Unguium) Pipeline, 2020
2.2 Most focused Mechanism of Action in Onychomycosis (Tinea Unguium) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Onychomycosis (Tinea Unguium) pipeline
2.5 Active Companies Developing Onychomycosis (Tinea Unguium) pipeline
3. ONYCHOMYCOSIS (TINEA UNGUIUM) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acea Biotech Inc
Almirall SA
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Photonamic GmbH & Co KG
Sanotize Research And Development Corp
5. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Onychomycosis (Tinea Unguium) Pipeline, 2020
2.2 Most focused Mechanism of Action in Onychomycosis (Tinea Unguium) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Onychomycosis (Tinea Unguium) pipeline
2.5 Active Companies Developing Onychomycosis (Tinea Unguium) pipeline
3. ONYCHOMYCOSIS (TINEA UNGUIUM) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acea Biotech Inc
Almirall SA
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Photonamic GmbH & Co KG
Sanotize Research And Development Corp
5. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ONYCHOMYCOSIS (TINEA UNGUIUM) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
